Suppression of inducible ventricular tachycardia by ibutilide in patients with coronary artery disease. Ibutilide Investigators

American Heart Journal
M A WoodJ T Vanderlugt

Abstract

Recent studies suggest that class III antiarrhythmic agents may have enhanced efficacy in the treatment of ventricular tachycardia. This study describes the first clinical assessment of the new class III agent ibutilide to suppress inducible monomorphic ventricular tachycardia (VT) in human beings. Fifty-five patients with coronary artery disease and inducible sustained monomorphic VT at baseline received either low (0.005 mg/kg + 0.001 mg/kg, load and maintenance infusion, respectively), middle (0.01 mg/kg + 0.002 mg/kg), or high dose (0.02 mg/kg + 0.004 mg/kg) infusions of ibutilide followed by repeat programmed ventricular stimulation. The mean age of the study group was 65.5 +/- 9.5 years and mean left ventricular ejection fraction was 36% +/- 11%. Of 48 evaluable patients, 21 (44%) were rendered noninducible after ibutilide, with no difference in efficacy among the three dosing groups (p = 0.83). Ventricular effective refractory periods, QTc interval, and ventricular monophasic action potential duration were prolonged over baseline at all tested cycle lengths. The QTc and action potential prolongation were dose related. Serious drug-related adverse reactions included sustained polymorphic VT in two patients (3.6%), spontan...Continue Reading

References

Nov 1, 1992·Pacing and Clinical Electrophysiology : PACE·J D FisherJ Roth
Jan 2, 1990·The American Journal of Cardiology·L F SoykaR B Spangenberg
Apr 1, 1984·Journal of Clinical Pharmacology·E M Vaughan Williams
Jul 1, 1996·Journal of the American College of Cardiology·K A EllenbogenJ T Vanderlugt

❮ Previous
Next ❯

Citations

Mar 25, 1999·Journal of Cardiovascular Electrophysiology·A J Camm, Y G Yap
Feb 7, 2001·Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine·K A Marill, T Runge
May 24, 2000·Progress in Pediatric Cardiology·A Dubin
Oct 30, 2015·Expert Opinion on Pharmacotherapy·J William SchleiferWin-Kuang Shen
Jun 24, 2004·Expert Opinion on Investigational Drugs·Anirban Choudhury, Gregory Y H Lip
Jun 2, 2005·Expert Opinion on Investigational Drugs·Sheila A Doggrell, Jules C Hancox

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.